ML390 is primarily utilized in research settings for its role as a selective inhibitor of heme oxygenase-1 (HO-1). It is employed in studies aimed at understanding the biological functions and pathways associated with HO-1, particularly in the context of oxidative stress, inflammation, and cancer. Researchers use ML390 to explore its potential therapeutic effects in diseases where HO-1 activity is implicated, such as neurodegenerative disorders, cardiovascular diseases, and certain types of tumors. By inhibiting HO-1, ML390 helps elucidate the enzyme's role in cellular protection and its impact on disease progression. This makes it a valuable tool in preclinical studies for developing targeted therapies.